Article
Oncology
Katarina Pinjusic, Olivier Andreas Dubey, Olga Egorova, Sina Nassiri, Etienne Meylan, Julien Faget, Daniel Beat Constam
Summary: This study reveals that Activin-A secretion by melanoma cells inhibits adaptive antitumor immunity by indirectly inhibiting CD8(+) T cell infiltration, regardless of BRAF status. It is also found that Activin-A/INHBA expression is correlated with resistance to anti-PD1 therapy in melanoma patients and impairs response to combination anti-cytotoxic T-Lymphocyte associated protein 4/anti-PD1 treatment in preclinical models.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2022)
Article
Oncology
Josep Malvehy, Igor Samoylenko, Dirk Schadendorf, Ralf Gutzmer, Jean-Jacques Grob, Joseph J. Sacco, Kevin S. Gorski, Abraham Anderson, Cheryl A. Pickett, Kate Liu, Helen Gogas
Summary: This study demonstrates that T-VEC induces systemic immune activity and modifies the tumor microenvironment, potentially enhancing the efficacy of combination immunotherapy with other agents.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2021)
Review
Biochemistry & Molecular Biology
Alice Indini, Francesco Grossi, Mario Mandala, Daniela Taverna, Valentina Audrito
Summary: Malignant melanoma, the most fatal skin cancer, has seen a shift in treatment strategies with the introduction of new inhibitors and immunotherapy. However, resistance to systemic treatments remains a challenge, driven by various mechanisms involving cancer metabolism, epigenetics, gene expression, and interactions within the tumor microenvironment. Biomarkers are needed to guide patient selection and treatment decisions.
Article
Oncology
Maud Plaschka, Valentin Benboubker, Maxime Grimont, Justine Berthet, Laurie Tonon, Jonathan Lopez, Myrtille Le-Bouar, Brigitte Balme, Garance Tondeur, Arnaud de la Fouchardiere, Lionel Larue, Alain Puisieux, Yenkel Grinberg-Bleyer, Nathalie Bendriss-Vermare, Bertrand Dubois, Christophe Caux, Stephane Dalle, Julie Caramel
Summary: This study reveals that ZEB1 expression in melanoma cells is associated with decreased CD8(+) T cell infiltration, leading to tumor immune evasion and resistance to immune checkpoint blockade. ZEB1 directly represses the secretion of T cell-attracting chemokines, such as CXCL10, and targeting ZEB1 may enhance the efficacy of immunotherapy in melanoma.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2022)
Review
Oncology
James Harber, Tamihiro Kamata, Catrin Pritchard, Dean Fennell
Summary: Malignant pleural mesothelioma (MPM) is a difficult-to-treat cancer, but recent trials on immune checkpoint blockade (ICB) have shown promising results. While TMB and PD-L1 may not predict ICB response in MPM, understanding the tumor immune microenvironment can lead to improved therapy outcomes.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2021)
Article
Oncology
Beatrice Thier, Fang Zhao, Simone Stupia, Alicia Brueggemann, Johannes Koch, Nina Schulze, Susanne Horn, Christoph Coch, Gunther Hartmann, Antje Sucker, Dirk Schadendorf, Annette Paschen
Summary: The activation of RIG-I signaling in melanoma cells can induce dedifferentiation, but these dedifferentiated cells are still highly sensitive to autologous immune responses, challenging the concept of melanoma dedifferentiation as an indicator of T cell resistance.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2022)
Article
Oncology
Marie Fournier, Laurent Mortier, Olivier Dereure, Sophie Dalac, Bastien Oriano, Stephane Dalle, Celeste Lebbe
Summary: This study suggests that HPD may be a subtype of disease characterized by rapid deterioration, and can be alleviated by strong-acting treatments.
EUROPEAN JOURNAL OF CANCER
(2023)
Article
Oncology
Veronique Roche, Victor Sandoval, Zachary Senders, Joshua Lyons, Claire Wolford, Mei Zhang
Summary: The study suggests that targeting myeloid components using BG34-200 can create systemic antitumor immune responses in advanced melanoma, improving the treatment outcome for patients who do not respond to current therapies.
Article
Immunology
Minjie Zhang, Mengna Shi, Yang Yu, Jianmin Sang, Hong Wang, Jianhong Shi, Ping Duan, Renshan Ge
Summary: Immunotherapy subtypes were identified in ovarian cancer (OC), and their association with prognosis and treatment sensitivity was explored. The study provides potential biomarkers for predicting prognosis and therapeutic targets for immunotherapy drug development.
Article
Oncology
Shaolong Leng, Gang Nie, Changhong Yi, Yunsheng Xu, Lvya Zhang, Linyu Zhu
Summary: Our study identified 36 prognostic genes and constructed a machine learning-derived immune signature (MLDIS) using ten machine learning algorithms. High MLDIS was associated with poor overall survival and showed good prediction performance in all cohorts. Additionally, high MLDIS had a positive prognostic impact on patients treated with anti-PD-1 immunotherapy.
CANCER CELL INTERNATIONAL
(2023)
Article
Oncology
Grace Heloise Attrill, Carina N. Owen, Tasnia Ahmed, Ismael A. Vergara, Andrew J. Colebatch, Jordan W. Conway, Kazi J. Nahar, John F. Thompson, Ines Pires da Silva, Matteo S. Carlino, Alexander M. Menzies, Serigne Lo, Umaimainthan Palendira, Richard A. Scolyer, Georgina Long, James S. Wilmott
Summary: This study found that specific subsets of CD8+ T cells were significantly associated with recurrence in high-risk patients with stage III melanoma treated with anti-PD-1 therapy. CD39+ tumor-resident memory cells were more prevalent in recurrence-free patients, while bystander T cells were more prevalent in patients who developed recurrence. The CD39+ Trms were located significantly closer to melanoma cells compared to bystander T cells.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2022)
Article
Oncology
Alex Frias, Luca Di Leo, Asier Antoranz, Loulieta Nazerai, Marco Carretta, Valerie Bodemeyer, Chiara Pagliuca, Christina Dahl, Giuseppina Claps, Giulio Eugenio Mandelli, Madhavi Dipak Andhari, Maria Pires Pacheco, Thomas Sauter, Caroline Robert, Per Guldberg, Daniel Hargbol Madsen, Francesco Cecconi, Francesca Maria Bosisio, Daniela De Zio
Summary: Loss of Ambra1 in melanoma affects the tumor immune microenvironment (TIME) and the antitumor immune response. It leads to changes in TIME composition and reduces the infiltration of regulatory T cells, resulting in accelerated tumor growth and decreased overall survival. However, loss of Ambra1 also sensitizes melanoma to anti-PD-1 treatment.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2023)
Article
Oncology
Katharina Filipski, Michael Scherer, Kim N. Zeiner, Andreas Bucher, Johannes Kleemann, Philipp Jurmeister, Tabea Hartung, Markus Meissner, Karl H. Plate, Tim R. Fenton, Jorn Walter, Sascha Tierling, Bastian Schilling, Pia S. Zeiner, Patrick N. Harter
Summary: A novel machine learning classifier based on DNA methylation data was developed to predict therapy responses in patients with metastatic melanoma undergoing immune checkpoint inhibition. The classifier utilizes large-scale DNA methylation data analysis to help estimate treatment responses in patients.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2021)
Article
Oncology
Michael Hwang, Jenna Vanliere Canzoniero, Samuel Rosner, Guangfan Zhang, James R. White, Zineb Belcaid, Christopher Cherry, Archana Balan, Gavin Pereira, Alexandria Curry, Noushin Niknafs, Jiajia Zhang, Kellie N. Smith, Lavanya Sivapalan, Jamie E. Chaft, Joshua E. Reuss, Kristen Marrone, Joseph C. Murray, Qing Kay Li, Vincent Lam, Benjamin P. Levy, Christine Hann, Victor E. Velculescu, Julie R. Brahmer, Patrick M. Forde, Tanguy Seiwert, Valsamo Anagnostou
Summary: Through machine learning, this study integrated the dynamics of peripheral blood immune cell subsets and predicted clinical outcomes for 239 patients with metastatic non-small cell lung cancer. The findings suggest that the integrated dynamics of peripheral blood cell counts, particularly changes in NLR, can predict therapeutic response better than traditional biomarkers like TMB and PD-L1 expression. Early changes in NLR were identified as a key predictor of treatment response.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2022)
Article
Oncology
Robin Reschke, Jovian Yu, Blake Flood, Emily F. Higgs, Ken Hatogai, Thomas F. Gajewski
Summary: In human melanoma metastases, CD45(+) cells and Sox10(+) cells are identified as the major cellular sources for CXCL10. CXCL10 within the tumor site serves as a positive prognostic factor for response to immunotherapy, and the use of RNAscope technique is feasible in paraffin tissue. Strategies supporting effector T cell recruitment through the induction of CXCL10 may enhance the efficacy of immunotherapy.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2021)
Article
Oncology
Stephanie A. Blankenstein, Johannes J. Bonenkamp, Maureen J. B. Aarts, Franchette W. P. J. van den Berkmortel, Christian U. Blank, Willeke A. M. Blokx, Marye J. Boers-Sonderen, Alfons J. M. van den Eertwegh, Margreet G. Franken, Jan Willem B. de Groot, John B. A. G. Haanen, Geke A. P. Hospers, Ellen W. Kapiteijn, Olivier J. van Not, Djura Piersma, Rozemarijn S. van Rijn, Karijn P. M. Suijkerbuijk, Astrid A. M. van der Veldt, Gerard Vreugdenhil, Hans M. Westgeest, Michel W. J. M. Wouters, Alexander C. J. van Akkooi
Summary: In patients with unresectable stage IIIC or IV melanoma, there was no significant difference in disease outcome for those previously staged with SLNB compared to those who were not staged with SLNB prior to the availability of adjuvant systemic therapy.
ANNALS OF SURGICAL ONCOLOGY
(2023)
Letter
Oncology
Monique K. van der Kooij, Arjen Joosse, Karijn P. M. Suijkerbuijk, Maureen J. B. Aarts, Franchette W. P. J. van den Berkmortel, Christian U. Blank, Marye J. Boers-Sonderen, Alfonsus J. M. van den Eertwegh, Jan Willem B. de Groot, John B. A. G. Haanen, Geke A. P. Hospers, Djura Piersma, Rozemarijn S. van Rijn, Astrid A. M. van der Veldt, Gerard Vreugdenhil, Hans M. Westgeest, Michel W. J. M. Wouters, Olaf M. Dekkers, Ellen Kapiteijn
BRITISH JOURNAL OF CANCER
(2023)
Article
Cardiac & Cardiovascular Systems
Jurrien H. Kuneman, Sophie E. van Rosendael, Pieter van der Bijl, Alexander R. van Rosendael, Pieter H. Kitslaar, Johan H. C. Reiber, J. Wouter Jukema, Martin B. Leon, Nina Ajmone Marsan, Juhani Knuuti, Jeroen J. Bax
Summary: This study compared the pericoronary adipose tissue (PCAT) attenuation between acute coronary syndrome and stable coronary artery disease patients. The results showed that the PCAT attenuation in culprit lesion precursors of acute coronary syndrome patients was significantly higher than nonculprit lesions and lesions of stable coronary artery disease patients. Therefore, PCAT attenuation may be a novel marker for identifying high-risk plaques.
CIRCULATION-CARDIOVASCULAR IMAGING
(2023)
Review
Oncology
Liselotte Tas, Inge Jedema, John B. A. G. Haanen
Summary: Treatment with tumor-infiltrating lymphocytes (TILs) has shown remarkable clinical responses in patients with advanced solid tumors. However, the current production process lacks effective selection for tumor reactivity and functional activity. This review highlights the limitations and proposes improvements to increase TIL efficacy.
CURRENT OPINION IN ONCOLOGY
(2023)
Article
Biochemistry & Molecular Biology
Tariq O. Faquih, N. Ahmad Aziz, Sarah L. Gardiner, Ruifang Li-Gao, Renee de Mutsert, Yuri Milaneschi, Stella Trompet, J. Wouter Jukema, Frits R. Rosendaal, Astrid van Hylckama Vlieg, Ko Willems van Dijk, Dennis O. Mook-Kanamori
Summary: Based on the data from three European cohorts, this study found that non-pathogenic CAG repeat sizes below 36 in the HTT gene are associated with abnormal metabolite levels, which may be mediated through lower BMI.
HUMAN MOLECULAR GENETICS
(2023)
Article
Biochemistry & Molecular Biology
Muhanad Ali, Miriam E. van Gent, Amy M. de Waal, Bjorn R. van Doodewaerd, Erik Bos, Roman I. Koning, Robert A. Cordfunke, Jan Wouter Drijfhout, Peter H. Nibbering
Summary: The formulation of SAAP-148 in PLGA nanoparticles improves its selectivity index and enables sustained release of the peptide. The nanoparticles exhibit favorable physiochemical properties and demonstrate increased activity against antimicrobial resistant bacteria and biofilms over time. This suggests that SAAP-148 nanoparticles have promising potential as a treatment for bacterial infections.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Pharmacology & Pharmacy
Miriam E. E. van Gent, Tom van Baaren, Sylvia N. N. Klodzinska, Muhanad Ali, Natasja Dolezal, Bjorn R. R. van Doodewaerd, Erik Bos, Amy M. M. de Waal, Roman I. I. Koning, Jan Wouter Drijfhout, Hanne Morck Nielsen, Peter H. H. Nibbering
Summary: Synthetic antibacterial and antibiofilm peptide (SAAP)-148 is an alternative treatment for chronic wound infections, but its therapeutic potential is limited due to its peptidic nature and cytotoxicity. Encapsulation of SAAP-148 in nanogels composed of OSA-modified HA overcomes these limitations. The formulated SAAP-148-loaded nanogels sustainably release the peptide and exhibit antimicrobial activity without cytotoxicity.
Article
Oncology
Stefanie L. Groenland, J. M. Janssen, C. M. Nijenhuis, N. de Vries, H. Rosing, S. Wilgenhof, J. V. van Thienen, J. B. A. G. Haanen, C. U. Blank, J. H. Beijnen, A. D. R. Huitema, N. Steeghs
Summary: The study examined the relationship between drug exposure and efficacy and toxicity in melanoma patients treated with dabrafenib plus trametinib. Results showed that trametinib exposure was related to survival, with a threshold of 15.6ng/mL. Patients with trametinib concentrations at or above this threshold had a significantly longer median overall survival compared to those with concentrations below the threshold. Exposure to dabrafenib and trametinib was not associated with clinically relevant toxicities.
CANCER CHEMOTHERAPY AND PHARMACOLOGY
(2023)
Article
Oncology
Isabella A. J. van Duin, Sjoerd G. Elias, Alfonsus J. M. van den Eertwegh, Jan Willem B. de Groot, Willeke A. M. Blokx, Paul J. van Diest, Tim Leiner, Joost J. C. Verhoeff, Rik J. Verheijden, Olivier J. van Not, Maureen J. B. Aarts, Franchette W. P. J. van den Berkmortel, Christian U. Blank, John B. A. G. Haanen, Geke A. P. Hospers, Anna M. Kamphuis, Djura Piersma, Rozemarijn S. van Rijn, Astrid A. M. van Der Veldt, Gerard Vreugdenhil, Michel W. J. M. Wouters, Marion A. M. Stevense-den Boer, Marye J. Boers-Sonderen, Ellen Kapiteijn, Karijn P. M. Suijkerbuijk
Summary: Since the introduction of BRAF(/MEK) inhibition and immune checkpoint inhibition (ICI), the prognosis of advanced melanoma has greatly improved. We investigated the relationship between time to first distant recurrence (TFDR) and patient outcomes after systemic treatment for advanced melanoma. The results showed that patients with a longer TFDR have prolonged PFS and OS, regardless of the type of treatment they received.
INTERNATIONAL JOURNAL OF CANCER
(2023)
Article
Oncology
Melissa M. de Meza, Willeke A. M. Blokx, Han J. Bonenkamp, Cristian U. Blank, Maureen J. B. Aarts, Franchette W. P. J. van den Berkmortel, Marye J. Boers-Sonderen, Jan Willem B. de Groot, John B. Haanen, Geke A. P. Hospers, Ellen W. Kapiteijn, Olivier J. van Not, Djura Piersma, Rozemarijn S. van Rijn, Marion A. Stevense-Den A. Boer, Astrid A. M. van Der Veldt, Gerard Vreugdenhil, Alfons J. M. van den Eertwegh, Karijn P. M. Suijkerbuijk, Michel W. J. M. Wouters
Summary: This study examines the adjuvant systemic therapy of in-transit melanoma (ITM) patients and compares the outcomes of different patient groups. The results indicate that ITM-only patients have similar recurrence-free survival and overall survival rates to non-ITM patients, while patients with both ITM and nodal disease have lower rates.
INTERNATIONAL JOURNAL OF CANCER
(2023)
Article
Oncology
Michiel C. T. van Zeijl, Jesper van Breeschoten, Liesbeth C. de Wreede, Michel W. J. M. Wouters, Doranne L. Hilarius, Christian U. Blank, Maureen J. B. Aarts, Franchette W. P. J. van den Berkmortel, Jan Willem B. de Groot, Geke A. P. Hospers, Ellen Kapiteijn, Djura Piersma, Rozemarijn S. van Rijn, Marion Stevense-den A. Boer, Astrid A. M. van der Veldt, Gerard Vreugdenhil, Marye J. Boers-Sonderen, Karijn P. M. Suijkerbuijk, John B. A. G. Haanen, Alfons J. M. van den Eertwegh
Summary: Despite treatment-related adverse events, ipilimumab plus nivolumab combination therapy is effective for advanced melanoma in phase III trials. Here, real-world safety and survival outcomes of ipilimumab plus nivolumab for advanced melanoma are reported.
JOURNAL OF IMMUNOTHERAPY
(2023)
Article
Infectious Diseases
Colin Bournez, Martijn Riool, Leonie de Boer, Robert A. Cordfunke, Leonie de Best, Remko van Leeuwen, Jan Wouter Drijfhout, Sebastian A. J. Zaat, Gerard J. P. van Westen
Summary: To combat infection, host organisms possess defense peptides, including antimicrobial peptides (AMPs), which can target a wide range of pathogenic microorganisms. Researchers have developed a machine learning model called CalcAMP that can predict the activity of AMPs. This model can help in identifying potential short AMPs quickly, which can be an effective solution to the growing issue of multi-drug resistance. CalcAMP is based on a new data set constructed from available public data on AMPs and experimental antimicrobial activities, and it can predict activity against both Gram-positive and Gram-negative bacteria.
Article
Cell Biology
Tetje C. van der Sluis, Guillaume Beyrend, Esme T. I. van der Gracht, Tamim Abdelaal, Simon P. Jochems, Robert A. Belderbos, Thomas H. Wesselink, Suzanne van Duikeren, Floortje J. van Haften, Anke Redeker, Laura F. Ouboter, Elham Beyranvand Nejad, Marcel Camps, Kees L. M. C. Franken, Margot M. Linssen, Peter Hohenstein, Noel F. C. C. de Miranda, Hailiang Mei, Adriaan D. Bins, John B. A. G. Haanen, Joachim G. Aerts, Ferry Ossendorp, Ramon Arens
Summary: Immune checkpoint therapy (ICT) has the potential to eliminate cancer, but the underlying mechanisms determining its effectiveness are not fully understood. By using high-dimensional single-cell profiling, this study investigates if the T cell landscape in peripheral blood can predict responses to combinatorial targeting of the OX40 costimulatory and PD-1 inhibitory pathways. The findings reveal dynamic activation states of therapy-responsive T cells and emphasize the importance of NK cell receptors and chemokine receptors in therapy-induced anti-tumor immunity.
CELL REPORTS MEDICINE
(2023)
Article
Biochemistry & Molecular Biology
Andreas Mackensen, John B. A. G. Haanen, Christian Koenecke, Winfried Alsdorf, Eva Wagner-Drouet, Peter Borchmann, Daniel Heudobler, Barbara Ferstl, Sebastian Klobuch, Carsten Bokemeyer, Alexander Desuki, Florian Lueke, Nadine Kutsch, Fabian Mueller, Eveline Smit, Peter Hillemanns, Panagiotis Karagiannis, Erol Wiegert, Ying He, Thang Ho, Qing Kang-Fortner, Anna Melissa Schlitter, Catrine Schulz-Eying, Andrew Finlayson, Carina Flemmig, Klaus Kuehlcke, Liane Preussner, Benjamin Rengstl, Oezlem Tuereci, Ugur Sahin
Summary: This study evaluated the safety and efficacy of CAR-T cell therapy targeting Claudin 6 (CLDN6) in relapsed/refractory CLDN6-positive solid tumors. Manageable toxicity was observed, and objective response rate and disease control rate were assessed for the relevant tumors.
Review
Cell Biology
Dixie Bakker, Walbert J. Bakker, Marcel W. Bekkenk, Rosalie M. Luiten
Summary: Non-melanoma skin cancers are common in Caucasians and can be burdensome for healthcare. Solid organ transplant recipients have a higher risk of developing these cancers due to immunosuppressive medication use. Different classes of immunosuppressants have varying effects on the incidence of skin cancers.